Being Tactical = Mo...
Health Care: Drugs
Inhibitex Inc. (INHX: NASDAQ)
$25.96 0.06 | 0.23%
02/10/12 - 04:00 PM ET
1.35M / 4.73M
Vol / Avg. Vol:25.91 / 25.90
Open / Prev. Close:25.91 - 25.96
Today's Range:2.15 - 25.91
52 Wk Range:137.29%
Performance YTD:TheStreet Rating:
Portfolios with INHX
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorFive Drug Stock Winners of ...
- ContributorStocks Rising On Unusal Vol...
- UserStock/ETF
- Contributor13 Biotech Stocks Bought an...
- Contributor10 Hep C Stocks on Wall Str...
- ContributorHep C Drug Stocks in the Sp...
- Contributor6 Penny Stocks for the Biot...
- User101
- Contributor5 Drug Stock Winners of 2010
Latest INHX Headlines from TheStreet
- 3 Industries and 3 Stocks Riding a 2012 M&A Boom 02.06.12 | 12:02 pm
- Idenix Falls Casualty to Gilead Hep C Hoopla 02.03.12 | 11:02 am
- Gilead Wows With New Hep C Data, Boxing Out Poor 2012 Guidance 02.03.12 | 07:02 am
- BioLineRx: Tuesday's Hot Hep C Drug Stock 01.24.12 | 11:01 am
- Idenix Pharma Buyout Likely: Survey 01.20.12 | 03:01 pm
- More Biotech Lessons Learned From JPM 2012 01.13.12 | 06:01 am
- Stocks Finish Higher; Alcoa Posts Loss 01.09.12 | 05:01 pm
- Stock Futures Rise After Euro Talks Kick Off 01.09.12 | 08:01 am
- Idenix Pharma's Hep C Drug Safe But Slow (And Ready For Sale) 01.09.12 | 08:01 am
- Stocks to Watch: Inhibitex, Alcoa (Update 1) 01.09.12 | 08:01 am
Press Releases for INHX
- Potentially Unfair Tender Offer For Inhibitex Triggers Shareholder-Claim Investigation By Securities Class Action Lawyers At Goldfarb Branham LLP - PR Newswire 01.11.12 | 11:01 am
- The Law Firm Of Levi & Korsinsky, LLP Announces Investigation Into Possible Breaches Of Fiduciary Duty By The Board Of Inhibitex, Inc. In Connection With The Sale Of The Company To Bristol-Myers Squibb Co. - Business Wire 01.10.12 | 07:01 pm
- Faruqi & Faruqi, LLP Announces Investigation Of Inhibitex, Inc. - Business Wire 01.10.12 | 07:01 pm
- Law Firm Brower Piven Announces Investigation Of Inhibitex, Inc. - Business Wire 01.10.12 | 03:01 pm
- Ryan & Maniskas, LLP Announces Investigation Of Inhibitex, Inc. - Business Wire 01.10.12 | 10:01 am
- Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Inhibitex, Inc. - Business Wire 01.09.12 | 04:01 pm
- Harwood Feffer LLP Announces Investigation Of Inhibitex, Inc. - Business Wire 01.09.12 | 01:01 pm
- The Law Firm Of Levi & Korsinsky, LLP Announces Investigation Into Possible Breaches Of Fiduciary Duty By The Board Of Inhibitex, Inc. In Connection With The Sale Of The Company To Bristol-Myers Squibb Co. - Business Wire 01.09.12 | 11:01 am
- Inhibitex, Inc. Shareholder Alert: The Briscoe Law Firm And Powers Taylor, LLP Investigate The Board Of Inhibitex, Inc. Concerning The Sale Of INHX To Bristol-Myers Squibb - PR Newswire 01.09.12 | 11:01 am
- Rigrodsky & Long, P.A. Announces Investigation Of Inhibitex, Inc.’s Agreement To Be Acquired By Bristol-Myers Squibb Company - Business Wire 01.09.12 | 09:01 am
Partner Headlines for INHX
- Momentum Trading: These 6 Stocks Are Up More Than 50% Already in 2012 - Benzinga 01.27.12 | 03:01 pm
- Biotech Equities Continue To Benefit From Discoveries And Acquisitions In 2012 - Seeking Alpha 01.27.12 | 09:01 am
- Earnings Preview: Bristol-Myers - Analyst Blog - Zacks 01.23.12 | 10:01 am
- The Zacks Analyst Blog Highlights: Gilead Sciences, Bristol-Myers Squibb, Inhibitex, Vertex Pharmaceuticals and Merck - Press Releases - Zacks 01.20.12 | 09:01 am
- Analyzing 5 Biotech Stocks And Their Takeover Potential - Seeking Alpha 01.13.12 | 08:01 am
- The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, Sanofi, Inhibitex, Gilead Sciences and Pharmasset - Press Releases - Zacks 01.10.12 | 09:01 am
- Afternoon Movers; Markets Moved Higher - Benzinga 01.09.12 | 04:01 pm
- Forget Dendreon, Inhibitex is the New Biotech Success Story - Benzinga 01.09.12 | 01:01 pm
- Ahead of Wall Street - January 9, 2012 - Ahead of Wall Street - Zacks 01.09.12 | 09:01 am
- BMY Kicks Off 2012 Pharma Deals - Analyst Blog - Zacks 01.09.12 | 09:01 am
